Bristol Myers Squibb CO Form 4 insider transactions

Bristol-Myers Squibb's EVP and Chief Financial Officer, David V. Elkins, reported the vesting of market share units and performance shares, along with new equity grants.

Bristol-Myers Squibb EVP Gregory Scott Meyers reported the vesting of 2,543 restricted stock units and the withholding of 833 shares for tax purposes.

Bristol-Myers Squibb President Benjamin Hickey converted restricted stock units into common shares and subsequently sold a portion for tax obligations.

Bristol Myers Squibb Director Phyllis R. Yale acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership.

Karen H. Vousden, a director at Bristol-Myers Squibb, acquired 3,996.367 Deferred Share Units, increasing her total beneficial ownership.

Bristol Myers Squibb Director Theodore R. Samuels II acquired 3,996.367 Deferred Share Units as part of a compensation plan.

Bristol Myers Squibb Director Derica W. Rice acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership to 39,324.809 units, aligning interests with shareholders.

Bristol Myers Squibb Director Paula A. Price acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership.

Bristol-Myers Squibb Director Michael R. McMullen acquired 3,996.367 deferred share units, increasing his beneficial ownership to 14,979.689 units.

Bristol-Myers Squibb Director Manuel Hidalgo Medina acquired 3,996.367 Deferred Share Units, increasing his beneficial ownership.

Bristol Myers Squibb Director Julia A Haller acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership to 37,903.154 units.

Bristol Myers Squibb Director Deepak Bhatt acquired 3,996.367 Deferred Share Units at $55.05 each, increasing his beneficial ownership to 19,241.818 units.

Bristol-Myers Squibb Director Peter J. Arduini acquired 3,996.367 Deferred Share Units, increasing his beneficial ownership.

Bristol Myers Squibb director Phyllis R. Yale acquired 648.869 deferred share units as part of her compensation plan, increasing her total beneficial ownership to 38,891.933 units.

A director at Bristol-Myers Squibb Company acquired 926.956 Deferred Share Units as part of a compensation plan.

Bristol-Myers Squibb Director Derica W. Rice acquired 695.217 Deferred Share Units, increasing total beneficial ownership to 34,934.653 units.

Bristol Myers Squibb Director Michael R. McMullen acquired 648.869 Deferred Share Units, increasing his beneficial ownership to 10,860.897 units.

Bristol-Myers Squibb Director Peter J. Arduini is set to acquire 625.695 deferred share units in a pre-planned transaction.

Bristol-Myers Squibb's EVP, Chief Commercial Officer, Adam Lenkowsky, acquired 22,568 restricted stock units, vesting over three years.

Bristol-Myers Squibb CEO Christopher S. Boerner reported the vesting of market share units and related stock transactions, including tax withholdings and a performance-based adjustment.

Bristol-Myers Squibb EVP Gregory Scott Meyers reported the vesting of 6,281 restricted stock units and the sale of 2,665 shares for tax purposes.

Karin Shanahan, EVP at Bristol-Myers Squibb, saw restricted stock units vest and sold shares to cover tax obligations.

Bristol-Myers Squibb's EVP, General Counsel, Cari Gallman, reported the acquisition of common stock through RSU vesting and subsequent tax-related share disposition.

Bristol Myers Squibb Director Phyllis R. Yale acquired 776.053 Deferred Share Units, increasing her beneficial ownership to 37,734.687 units.

Theodore R. Samuels II, a director at Bristol Myers Squibb, acquired 1,108.647 Deferred Share Units as part of his compensation.

Bristol-Myers Squibb Director Derica W. Rice acquired 831.486 Deferred Share Units as part of her compensation, increasing her total beneficial ownership to 33,784.279 units.

Bristol-Myers Squibb Director Michael R. McMullen increased his beneficial ownership of Deferred Share Units by 776.053 units on September 30, 2025, as part of a pre-arranged plan.

Bristol-Myers Squibb Director Peter J. Arduini acquired 748.337 Deferred Share Units, increasing his total beneficial ownership to 64,620.164 units.

Bristol-Myers Squibb's EVP and CFO, David V. Elkins, sold 56,000 shares of common stock for $47.33 per share, executed under a pre-arranged 10b5-1 trading plan.

A Bristol-Myers Squibb executive reported a future transaction under a 10b5-1 plan involving RSU conversion and tax-related share sale.